纤溶酶原激活物抑制剂-1的研究进展
| 作者: |
1蔡雪蓉,
1张学亚,
1潘敬新
1 福建医科大学附属第二医院血液内科，福州 362000 |
| 通讯: |
张学亚
Email: jakey@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.02.032 |
| 基金: | 福建省母婴健康应用技术创新课题(XJM1805)。 |
摘要
纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1，PAI-1)作为体内组织型纤溶酶原激活物(tissue-type plasminogen activator，t-PA)和尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator，u-PA)的主要抑制剂，与动静脉血栓、出血和凝血异常、细胞迁移密切相关，进而引起缺血性脑卒中、冠心病、静脉血栓、肿瘤转移、出血、股骨头坏死、流产等一系列疾病的发生发展。同时，体内血浆PAI-1活性水平又受血脂、血糖等调节，进一步参与肥胖、糖尿病、高脂血症等疾病的进程，又影响着上述相关疾病的预后。
关键词：
纤溶酶原激活物抑制剂-1；组织型纤溶酶原激活物；尿激酶型纤溶酶原激活物；血栓；出血；肿瘤
Research progress in plasminogen activator inhibitor 1
CorrespondingAuthor: ZHANG Xueya Email: jakey@sina.com
DOI: 10.3978/j.issn.2095-6959.2020.02.032
Foundation: This work was supported by the Fujian Province Maternal and Child Health Application Technology Innovation Project, China (XJM1805).
Abstract
Plasminogen activator inhibitor 1 (PAI-1), as the main inhibitor of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) in body, is closely related to arteriovenous thrombosis, abnormal coagulation and cell migration, which further leads to the occurrence and development of a series of diseases including ischemic stroke, coronary heart disease, venous thrombosis, tumor metastasis, hemorrhage, femoral head necrosis and abortion. Meanwhile, the level of plasma PAI-1 in the body is regulated by blood lipids and blood glucose, which further involves obesity, diabetes, hyperlipidemia and other diseases, and affects the prognosis of the above-mentioned related diseases. PAI-1 research covers a wide range of areas.
Keywords：
plasminogen activator inhibitor 1; tissue-type plasminogen activator; urokinase-type plasminogen activator; thrombus; bleeding; tumour